CTT Pharmaceutical Holdings Signs LOI for US Clinical Trials

CTT Pharmaceutical Holdings, Inc. (OTCQB:CTTH), based in Tampa, Florida, has entered into a Letter of Intent (LOI) with a United States company. This collaboration aims to conduct clinical trials and testing on various potential nicotine products for CTT Pharma. The agreement, if finalized, would allow CTT to independently market its products within the US using its patented technology. The company plans to update shareholders as further information becomes available.

CTT specializes in the development of thin film oral drug delivery systems. These systems are designed for rapid onset, enhanced patient convenience, and efficient absorption. The company's patented platform offers a novel alternative to traditional dosage forms across pharmaceutical, therapeutic, and nutraceutical markets. CTT is committed to integrating scientific validation and scalable manufacturing to support its long-term growth.